Search for stocks /

ANLON HEALTHCARE LIMITED Q2 & H1 FY26 Concall Decoded:116% YoY revenue growth, PAT nearly 4x, and management dreaming in metric tons.


1. Opening Hook

Just when investors were busy complaining about pharma margins and China dumping APIs, Anlon Healthcare walked into Q2 FY26 like, “Hold my reactor.” While most mid-cap pharma calls are apology tours for margins, this one was a victory lap disguised as a compliance lecture. Revenues more than doubled, profits went gym-mode, and management casually threw around numbers like 1,100 MT capacity and ₹500+ crore revenue dreams.

Of course, nothing spices up a concall like greenfield plants, inorganic acquisitions, and regulators who might knock “once in two years… or tomorrow.” Between DMFs, CDMO teasers, and China-plus-one chest-thumping, this call had everything—except humility.

Stick around. It starts impressive, gets ambitious, and by the end, management is basically planning Anlon FY28 already.


2. At a Glance

  • Revenue ₹52.3 cr (Q2): Up 116% YoY — apparently, growth is organic if you try hard enough.
  • EBITDA ₹13.8 cr: Up 82% — operating leverage finally clocked in.
  • PAT ₹9.3 cr: Nearly 4x — profits didn’t just grow, they sprinted.
  • H1 Revenue ₹85.5 cr: Up 38% — not flashy, but very steady.
  • Capacity Utilisation 84%: Factory breathing hard, still asked to run faster.

3. Management’s Key Commentary

“Total income stood at ₹52.32 crore, more than 2x YoY.”
(Growth so strong, even spreadsheets are impressed 😏)

“PAT increased nearly four times due to operating leverage.”
(Margins discovered gravity works both ways.)

“We received ANVISA approval with zero observations.”
(Regulators blinked first. Rare pharma moment.)

“We have 21 DMFs filed across regulated markets.”
(Paperwork Olympics — Anlon won gold.)

“Rajkot facility is operating at 84% capacity utilisation.”
(Machines sweating, management smiling.)

“CDMO commercialization expected in Q3 FY27.”
(Not today, but definitely in the investor deck.)

“We aim for 30%+ revenue CAGR over the next three years.”
(Ambition dial turned to ‘bold’, economy be damned.)


4. Numbers Decoded

MetricQ2 FY26YoY Trend
Revenue₹52.3 cr+116%
EBITDA₹13.8 cr+82%
EBITDA Margin~26%Stable
PAT₹9.3 cr~4x
H1 PAT₹12.9 cr2x

Decoded: Growth is real, margins are holding, and profits finally caught up. The numbers scream execution — but also scream capacity constraint incoming.


5.

Lalitha Diwakarla

Leave a Reply

Don't Miss

error: Content is protected !!